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Abstract
Chlamydia pneumoniae is responsible for up to 20% of community acquired pneumonia and can exacerbate chronic
inflammatory diseases. As the majority of infections are either mild or asymptomatic, a vaccine is recognized to have the
greatest potential to reduce infection and disease prevalence. Using the C. muridarum mouse model of infection, we
immunized animals via the intranasal (IN), sublingual (SL) or transcutaneous (TC) routes, with recombinant chlamydial major
outer membrane protein (MOMP) combined with adjuvants CTA1-DD or a combination of cholera toxin/CpG-
oligodeoxynucleotide (CT/CpG). Vaccinated animals were challenged IN with C. muridarum and protection against
infection and pathology was assessed. SL and TC immunization with MOMP and CT/CpG was the most protective,
significantly reducing chlamydial burden in the lungs and preventing weight loss, which was similar to the protection
induced by a previous live infection. Unlike a previous infection however, these vaccinations also provided almost complete
protection against fibrotic scarring in the lungs. Protection against infection was associated with antigen-specific
production of IFNc, TNFa and IL-17 by splenocytes, however, protection against both infection and pathology required the
induction of a similar pro-inflammatory response in the respiratory tract draining lymph nodes. Interestingly, we also
identified two contrasting vaccinations capable of preventing infection or pathology individually. Animals IN immunized
with MOMP and either adjuvant were protected from infection, but not the pathology. Conversely, animals TC immunized
with MOMP and CTA1-DD were protected from pathology, even though the chlamydial burden in this group was equivalent
to the unimmunized controls. This suggests that the development of pathology following an IN infection of vaccinated
animals was independent of bacterial load and may have been driven instead by the adaptive immune response generated
following immunization. This identifies a disconnection between the control of infection and the development of
pathology, which may influence the design of future vaccines.
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Introduction
Serological evidence suggests that 80% of people will contract a
C. pneumoniae respiratory tract infection at one point in their
lifetime [1]. In addition to respiratory tract infections, C. pneumoniae
infections are implicated in the exacerbation of cardiovascular
disease, asthma, chronic obstructive pulmonary disease, multiple
sclerosis, Alzheimer’s disease and reactive arthritis [2,3]. Many of
these diseases have multi-billion dollar healthcare expenditures
and are leading causes of morbidity and mortality in most nations.
Confounding the matter of infection control, most acute C.
pneumoniae respiratory infections are difficult to diagnose and treat
[4,5]. Furthermore, around 75% of first infections occur between
the ages of 5–14 years [6], highlighting the need for early
intervention to prevent infection and the potential predisposition/
exacerbation of chronic inflammatory diseases. Consequently,
development of a vaccine is most logical solution suited to
controlling the spread of infection.
Chlamydiae are obligate intracellular pathogens that infect
through and predominantly reside in the mucosal epithelium.
Protection against infection therefore, is reliant on the induction of
a mucosal immune response at the anatomical portal of entry of
the invading pathogen [7]. Vaccines targeted to mucosal epithelia,
without the necessity for needles, elicit mucosal immunity by
stimulating local innate cell populations that are preconditioned to
generate adaptive immune responses at mucosal surfaces. How-
ever, as immunological tolerance is often the default response to
mucosal antigen exposure, any mucosal vaccine must overcome
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this in order to elicit robust and long-lived mucosal immunity.
Unfortunately, a major obstacle to the development of an effective
vaccine for Chlamydia, and other mucosal pathogens, is the lack of
potent adjuvants proven to elicit protective responses at mucosal
surfaces.
There is a need for further research and development of new
mucosal adjuvants, however, vaccine safety cannot be compro-
mised. In 2001, the mucosal vaccine NasalfluH was withdrawn
from the market due to facial paresis (Bell’s palsy) developing in
some recipients. This was later attributed to toxicity of the
enterotoxic adjuvant (heat-labile toxin – LT, a bacterial toxin
derived from Escherichia coli) when administered by the nasal route
[8]. Interestingly, the same adjuvant applied topically can be
equally immunogenic without the inherent toxicity [9]. This shows
that utilizing different routes of immunization can limit the toxicity
associated with certain adjuvants like LT and CT, whilst still
harnessing their immunomodulatory benefits.
The detoxification of the enterotoxins such as CT and LT is also
a growing area of research. This is because the nasal route of
immunization is still of particular interest for human vaccines
designed to protect against mucosal pathogens. CTA1-DD consists
of the enzymatically active CTA1 subunit of CT, genetically linked
to a dimer of an immununoglobulin (Ig)-binding domain (D) from
the staphyloccocal protein A [10]. Inclusion of the DD moiety
targets the adjuvant’s immunogenic activity primarily to B cells
expressing surface Ig [11]. As a result, CTA1-DD retains the
adjuvanticity of the native holotoxin, but most importantly, is up
to 1000-fold less toxic in primates when given IN [12]. Promoting
both antibody and cell-mediated responses, CTA1-DD has been
shown to enhance protection against a number of different viral
and bacterial mucosal pathogens [12–18]. CTA1-DD therefore
represents a new generation of non-toxic mucosal adjuvants. The
ability of CTA1-DD however to confer protection against a
chlamydial respiratory tract infection and the associated pathology
is yet to be investigated.
CT/CpG, when combined with MOMP, has been shown to
elicit good protection against a respiratory tract chlamydial
challenge [19] and can be used for comparison with the new
generation adjuvant CTA1-DD. Despite the potential for toxic
side effects of the CT/CpG combination if administered IN, the
same adjuvant combination applied via SL or the TC routes can
be equally immunogenic in animal models [19,20], without the
inherent toxicity. In the present study we compared two adjuvants,
CTA1-DD and the CT/CpG combination, together with
MOMP. Animals were vaccinated with these two different
vaccines via three different needle-free routes of immunization
(IN, SL and TC), chosen for their abilities to elicit mucosal
immunity in the lungs [21]. Following immunization, the
induction of systemic and mucosal immune responses were
quantified and compared with the protection conferred against
infection and pathology following a respiratory tract challenge
with C. muridarum.
Methods
Ethics statement
This study was approved by the Queensland University of
Technology Animal Ethics Committee (Approval number
0800000432) and carried out in strict accordance with any
recommendation. All procedures were performed under anesthe-
sia, and all efforts were made to minimize suffering.
MOMP recombinant and Chlamydia muridarum
purification
Recombinant C. muridarum MOMP was purified from the E. coli
(DH5a[pMMM3]) clone transformed with the pMAL-c2 ampi-
cillin-resistant vector encoding the recombinant maltose-binding
protein fusion protein (MOMP-MBP) as previously described [19].
Endotoxin levels were quantified using ToxinSensorH chromo-
genic Limulus amebocyte lystate (Genscript – Life Research, VIC,
Australia) and reduced using DetoxiGelH (Thermo Fischer
Scientific, IL, USA) to 0.044EU/mL, below that capable of
stimulating an immune response by the IN route [11]. C. muridarum
(Weiss strain; ATCC VR-123, VA, USA), formerly mouse
pneumonitis biovar of C. trachomatis, was cultured and purified as
previously described [22].
Immunization protocols
Mice were sourced from the Animal Resource Centre (WA,
Australia) at 6 weeks of age. Mice were immunized on days 0, 7,
14 and 28 via either IN, TC or SL routes. This immunization
schedule was chosen because it will allow a retrospective
comparison between past and present work [18,19,23–25].
Animals in the IN group were lightly anesthetized with 4%v/v
isofluorane (Abbott Australasia, NSW, Australia). The anesthe-
tized mice were placed on their backs, held at a downward angle
then immunized with MOMP (100 mg) and either CTA1-DD
(MIVAC, The University of Go¨teborg) (20 mg) or CT (List
Biological Laboratories – Sapphire Biosciences, NSW, Australia)
(5 mg) plus CpG-ODN 1826c (59-TCC ATG ACG TTC CTG
ACG TT-39) (Sigma-Aldrich, NSW, Australia) (10 mg) mixed in a
10 mL volume, 5 mL applied to each nare. Animals in the TC
group were anesthetized with an intraperitoneal (IP) injection of
ketamine (100 mg/kg) (Parnell Laboratory, NSW, Australia) and
xylazine (10 mg/kg) (Bayer, NSW, Australia). A 1.5 cm2 area of
skin on the back of mice at the base of the tail was shaved using
clippers, with care taken not to break the skin. The skin was pre-
treated first with acetone, then with a solution containing
dodecylpyridinium chloride (DPC) (0.33%w/v), isopropyl myris-
tate (IPM) (0.33%w/v) and methyl pyrolidone (MPR) (0.33%w/v)
[26] and then rehydrated with phosphate buffered saline (PBS).
Mice then received granulocyte-macrophage colony-stimulating
factor (GM-CSF) (Invitrogen, VIC, Australia) (12.5 ng) [25] with
MOMP (200 mg) and either CTA1-DD (20 mg) or CT (10 mg) plus
CpG-ODN 1826c (10 mg) mixed in a volume of 50 mL. The
immunization was contained for a 24 hr time period using a patch
system consisting of gauze, Opsite FlexifixH (Smith & Nephew,
QLD, Australia) and MicroporeH surgical tape (3M, QLD,
Australia). The SL group was also anesthetized with ketamine
and xylazine. MOMP (100 mg) mixed with either CTA1-DD
(20 mg) or CT (5 mg) plus CpG-ODN 1826c (10 mg) in a 7 mL
volume was applied directly to the ventral side of the tongue and
left for 1 hr with the head of the mice maintained in ante-flexion.
The antigen and adjuvant dosages used for each route of
immunization were selected by their ability to elicit optimal
antigen-specific cell-mediated and humoral responses (data not
shown). Each route included antigen (MOMP) alone, adjuvant
alone (CTA1-DD or CT/CpG) and unimmunized (PBS) control
groups. Animals were euthanized 7 days after their final boost
using LethabarbH (200 mg/kg) (Virbac, NSW, Australia) delivered
IP.
Lymphocyte proliferation and cytokine analysis
The spleen and mediastinal lymph nodes (MdLN) of mice were
mechanically disrupted through 70 mm nylon filters (BD Biosci-
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ence, NSW, Australia). The red blood cells were lysed using red
blood lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 100 mM
EDTA, pH 7.35) for 5 min on ice. Lymphocytes from each tissue
were resuspended in complete Dulbecco’s minimal essential
medium (DMEM) (5%v/v fetal calf serum (FCS), 4 mM L-
glutamine, 50 mg/mL gentamycin, 100 mg/mL streptomycin
sulfate) (Invitrogen) containing 50 mM b-mercaptoethanol and
seeded into a U-bottom 96-well plates (56105 cells/well). Lym-
phocytes were then supplemented with either normal media
(unstimulated) or stimulated with media containing MOMP
(10 mg/well) for 72 hr at 37uC with 5% CO2. Following the
incubation, 100 mL of media was removed and stored at 280uC
for analysis of antigen-specific cytokine production. Cells were
then incubated with 0.5 mCi 3H-thymidine/well for an additional
14 hr time period. The incorporation of 3H-thymidine was
assessed using a Wallac 1450–030 MicroBeta TriLux Liquid
Scintillation and Luminescence Counter (PerkinElmer, VIC,
Australia). Results were expressed as a stimulation index; dividing
counts per minute (cpm) of the MOMP stimulated cultures by the
cpm of the media background.
Pooled supernatants from stimulated immune cell preparations
were analyzed for levels of IFNc, IL-4, IL-10 and IL-17 using a
customized BioPlex Mouse Express Pro Cytokine Assay 4-plex
(Biorad Laboratories – Life Sciences, VIC, Australia) according to
the manufacturer’s instructions and read on a Bioplex-200 system
with Luminex xMapH technology (Biorad Laboratories). TNFa
levels were also detected from the pooled supernatant using the
DuoSet ELISA development system (R&D systems – Sapphire
Biosciences) according the manufacturer’s instructions.
MOMP-specific antibodies
MOMP-specific antibodies were quantified by ELISA as
previously described [19]. Briefly, 96-well plates were incubated
overnight with 2 mg/well of MOMP in 50 mL of borate buffered
saline (0.5M boric acid, 1.5M NaCl, pH 8.4). The following day
plates were washed with PBS 0.05%v/v Tween20H (PBST) and
then blocked with 5%v/v FCS, PBST for 2 hr at 37uC. Samples
were serially diluted in the MOMP-coated plate using PBST and
incubated at 37uC for 1 hr. Plates were washed thoroughly with
PBST and then incubated with rabbit horseradish peroxidase
(HRP)-conjugated anti-mouse IgA, IgG, IgG1 and IgG2a (South-
ern Biotech – In vitro Technologies, VIC, Australia). The
substrate, 3,3,5,5-tetramethylbenzidine in a phosphate citrate
buffer (Sigma-Aldrich), was added to each well and incubated
for approximately 10 min at room temperature. The reaction was
stopped by the addition of 1M H2SO4 and the OD450nm was
measured on an xMarkH microplate spectrophotometer (Biorad
Laboratories). Endpoint titers were calculated for all samples using
non-linear regression analysis and background absorbance of
PBST plus two standard deviations (SD). Only those animals
vaccinated with the antigen induced MOMP-specific antibodies,
whereas those in unimmunized and adjuvant only control groups
did not (data not shown).
In vitro neutralization of C. muridarum infection
Lavage and serum samples, diluted 1/10 in complete DMEM,
were incubated with 103 inclusion-forming units (IFUs) of purified
C. muridarum in a 100 mL volume for 1 hr at 37uC with 5% CO2.
This suspension was then applied to confluent McCoy cell
monolayers in a 48-well plate and incubated for 3 hr. Following
incubation the antibody/Chlamydia suspension was removed, the
monolayer washed with PBS and replaced with media containing
1 mg/mL of cycloheximide. The infection was stopped after 24 hr
by fixing with methanol for 10 min. Each well was blocked
overnight at 4uC with a solution containing 5%v/v FCS, 0.05%w/
v sodium azide and PBST. Cells were then incubated with a 1/500
dilution of a sheep anti-C. muridarum recombinant MOMP-specific
polyclonal antibody (produced by the Institute of Medical and
Veterinary Science, SA, Australia, as previously described [19]) in
blocking solution for 1 hr at 37uC. Each well was rinsed
thoroughly with PBST following incubation, then stained with
1 mg/mL of donkey anti-sheep AlexaFluor-488 secondary anti-
body (Invitrogen) and 10 ng/mL 4’,6-diamidino-2-phenylindole,
dihydrochloride (DAPI) (Invitrogen) for 1 hr at 37uC. Each well
was then washed with PBST and inclusions were enumerated by
fluorescent microscopy. Images from three random fields of view
were taken from each well using a Nikon Eclipse TE2000-U
fluorescent inverted microscope fitted with a Nikon Digital Eclipse
DXM 1200C camera (Nikon Australia, NSW, Australia). Chla-
mydial inclusion and host cell nuclei were counted simultaneously
using MetaMorph Imaging Series 7.6 software (Molecular Devices
– SDR Clinical Technology, NSW, Australia). Percentage
neutralization was determined using the equation % neutraliza-
tion = [% cells infected (post-immunization) - % cells infected
(pre-immunization)] / % cells infected (no sample – media).
Intranasal C. muridarum challenge and monitoring
The respiratory tract challenge was conducted as previously
described [19]. Briefly, seven days after the final boost animals
were challenged IN with 103 IFU of purified C. muridarum, in a
10 mL volume, 5 mL applied to each nare. The live infection
control group was infected six weeks prior to re-challenge. All
animals were weighed daily to monitor the development of a lung
infection indirectly through cachexia [27].
Quantification of chlamydial burden in the respiratory
tract tissues
Quantification of the recoverable amount of Chlamydia from
lung homogenates was performed as previously described [19].
The lungs from each mouse were homogenized in 320 mL of
sucrose phosphate glutamine (219 mM sucrose, 3.8 mM
KH2PO4, 8.6 mM Na2HPO4 and 4.9 mM glutamic acid,
pH 7.0) using an OMNI TH tissue homogenizer with the 7 mm
saw-toothed stainless steel attachment (OMNI International, GA,
USA). Total genomic DNA was extracted from an overnight
proteinase K digest of 50 mL of tissue homogenate using the
Wizard Genomic DNA Purification Kit (Promega, NSW,
Australia) according to the manufacturer’s instructions. Quantita-
tive real-time PCR (qRT-PCR) was used to determine C.
muridarum DNA levels in total mouse lung genomic DNA using a
standard curve generated from known copies of the outer
membrane protein A (ompA) PCR product. The primer sequence
used in the qRT-PCR amplification of ompA gene encoding the
MOMP of C. muridarum is as follows: 59-GCC GTT TTG GGT
TCT GCT T-39 and 59-CGA GAC GTA GGC TGA TGG C-39
(Sigma-Aldrich). Each reaction contained a final concentration of
1 mM of forward/reverse primers, 200 mM dNTP’s, 1.5 mM
MgCl2, 1X buffer, 0.15X SYBR green, and 5U of Platinum Taq
polymerase (Invitrogen) made up to a final 20 mL volume using
sterile endonuclease-free water. Cycling conditions were 95uC
denaturation for 20 sec, followed by a 64uC annealing for 20 sec
and a 72uC extension for 15 sec repeated for a total of 30 cycles.
qRT-PCR was performed using the Corbet Rotorgene Q
(QIAGEN, VIC, Australia).
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Histopathology
The lungs from each mouse were excised and preserved by
fixing in 70%v/v ethanol. Fixed tissues were then imbedded in
paraffin, sectioned (5 mm) and stained with Masson’s trichrome for
evaluation of fibrosis (QML Diagnostics, QLD, Australia).
Sections were scored, by three individuals in a blinded fashion,
based on inflammation and scaring of the lung tissue (Table 1).
The final results were the average of all scores.
Statistical analysis
All data is presented as the mean 6 SD. All statistics were
performed using GraphPad PrismH version 5.00 (GraphPad
Software Inc, CA, USA). Significant differences were determined
using a one-way analysis of variance (ANOVA) with Tukey’s post-
test. Significance was set at P,0.05 for all tests. P.0.05 (not
shown), 0.01–0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
Results
Protection against infection following live C. muridarum
intranasal challenge
Firstly, we assessed whether either vaccine was capable of
preventing the development of pneumonia indirectly through
cachexia. Unimmunized animals developed severe cachexia
following an IN infection (Figure 1). The percentage weight loss
in unimmunized animals peaked on day 9 p.i at approximately
7%. The live infection control animals that had recovered from a
primary infection were strongly protected against weight loss
following re-infection. This group began regaining weight by day 4
p.i, significantly faster than the unimmunized animals at day 10 p.i
(P,0.001). The no infection control group had a net positive
weight gain over the 10 day time period, which was significant
when compared to infected control animals (P,0.001) and
indicated that cachexia was absent in uninfected animals.
Immunization with MOMP and CT/CpG, by any route,
significantly protected animals from the weight loss associated
with a chlamydial respiratory tract challenge (P,0.05–0.01)
(Figure 1A). SL and TC immunization with MOMP and CT/
CpG also provided a significant level of protection from the overall
magnitude of cachexia over the duration of the infection when
compared to the antigen, adjuvant and unimmunized controls
(P,0.05–0.01) (Figure 1C). Interestingly, only IN immunization
with MOMP and CTA1-DD significantly prevented weight loss
(P,0.05) when compared to the unimmunized control (Figure 1B).
The protection against weight loss conferred by this vaccination
was equivalent to the live infection control group. IN immuniza-
tion with MOMP and CTA1-DD also induced a comparable level
of protection against weight loss as MOMP and CT/CpG
delivered by the same route. Neither SL nor TC immunization
with MOMP and CTA1-DD prevented the development of
cachexia following infection.
The bacterial burden in the lung tissues was then quantified
from each group to validate cachexia results. All unimmunized
animals were PCR positive for C. muridarum following challenge
(Figure 2), with bacterial loads in excess of 46104 copies/mg of
gDNA. The live infection control group was negative for
chlamydial DNA at day 10 p.i. This absence of infection in the
live infection control group supports the strong resistance to re-
infection indicated by the weight loss data (Figure 1). No
chlamydial DNA could be detected in the uninfected control
group. The vaccinations that were protective against weight loss
also greatly reduced the bacterial burden in the lungs at the peak
of infection (Figure 2). Immunization with MOMP and CT/CpG,
by IN, SL and TC routes, significantly reduced levels of
recoverable bacterial DNA when compared to the unimmunized
controls (P,0.05). Conversely, MOMP and CTA1-DD was only
protective following IN administration (P,0.05). TC and SL
immunization with MOMP and CTA1-DD, which failed to
prevent weight loss (Figure 1), also induced no significant
reduction in bacterial DNA (Figure 2).
Protection against pathology following live C. muridarum
intranasal challenge
We next determined whether either vaccine was capable of
preventing the fibrotic scarring associated with an active
chlamydial pulmonary infection. Lung tissues taken from infected,
unimmunized animals showed significant collagen deposition and
lung consolidation (Figure 3A). The live infection control group,
strongly resistant to re-infection (Figure 1 and 2), showed a similar
level of fibrosis in the lungs to the naive unimmunized animals
(Figure 3B). The mock infection control group displayed no
evidence of fibrotic scarring when compared to the infection
controls (unimmunized and live infection control) (P,0.001).
Animals immunized with MOMP and CT/CpG via the TC and
SL routes, which were shown to provide protection against
cachexia and the lung chlamydial burden (Figure 1 and 2), were
also significantly protected from pathology when compared to the
unimmunized controls (P,0.05) (Figure 3B). Neither vaccine
delivered IN protected against pathology (Figure 3B), despite
reducing weight loss and bacterial burden (Figure 1 and 2). The
greatest protection against fibrotic scarring however was seen in
animals immunized by the TC route with MOMP and CTA1-
DD, where the pathology score of this group was equivalent to that
of uninfected animals (Figure 3B). Interestingly, these animals were
not significantly protected against weight loss or chlamydial
burden (Figure 1 and 2).
Antigen-specific proliferation and cytokine production
by splenocytes
As protection against a chlamydial infection is predominantly
driven by the cell-mediated response [28], we examined antigen-
specific proliferation and cytokine secretions by lymphocytes
Table 1. Histopathological scoring system for mouse lungs.
Fibrosis score Description Inflammation
0 Lack of fibrosis around tissue Absent
1 Some fibrosis around tissue Mild
2 Some tissue has significant fibrosis or majority of tissue has some fibrosis Moderate
3 The majority of tissue has significant fibrosis Severe
doi:10.1371/journal.pone.0061962.t001
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Figure 1. Percentage weight change of animals following IN challenge with C. muridarum. Percentage weight change was calculated by
comparing the pre-infection body weight to daily p.i body weights. The figure depicts the effect of vaccination with MOMP and (A) CT/CpG- or (B)
CTA1-DD-based vaccines on weight loss following IN challenge infection. Unimmunized (primary infection), live infection (secondary infection) and
no infection controls are also included. (C) Area under the curve (AUC) analysis of percentage weight change was the total area, of both negative and
positive peaks in weight change, over the 10 day course of infection in arbitrary units. Results are presented as the mean6 SD. Significant differences
were determined using a one-way ANOVA with Tukey’s post-test by comparing the weight changes between groups at the same point in time. One P
value, the most significant, is given for groups showing a significant change. Significance was set at P,0.05 for all tests. P.0.05 (not shown), 0.01–
0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g001
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isolated from the spleen and MdLN following in vitro re-stimulation
with MOMP. IN immunization with either vaccine (MOMP and
CTA1-DD or CT/CpG) elicited a significant increase in MOMP-
specific proliferation by splenocytes when compared to the
unimmunized control group (P,0.001) (Figure 4A). MOMP-
specific proliferation was also significantly elevated in animals
immunized with MOMP and CT/CpG via either the SL (P,0.01)
or TC routes (P,0.001) when compared to the unimmunized
controls.
Cytokines were only detected above background levels when
splenocytes were shown to proliferate significantly in response to
MOMP stimulation (Figure 4B). Immunization MOMP and CT/
CpG, by any route, resulted in significant increase in cytokine
secretions following in vitro stimulation with MOMP. The MOMP
and CTA1-DD vaccine induced antigen-specific cytokine secre-
tions by splenocytes when delivered via the IN and TC routes.
Production of IFNc was equal in animals receiving either IN
delivered vaccine, but this was significantly more in mice TC
immunized with MOMP and CT/CpG (P,0.05). IFNc was only
secreted by stimulated splenocytes isolated from animals IN
immunized with MOMP and CTA1-DD. A significant increase in
secretions of TNFa were also detected in all groups immunized
with MOMP and CT/CpG regardless of route (P,0.001).
Immunization with MOMP and CTA1-DD primed splenocytes
to secrete a significant amount of TNFa following re-stimulation,
but only when the vaccine was delivered IN (P,0.001). Antigen-
specific IL-17 production was highest in IN vaccinated animals
and was equivalent between adjuvants. With the exception of the
SL immunization with MOMP and CTA1-DD, IL-17 was also
secreted by splenocytes isolated from all other vaccine groups, but
at lower levels than in IN immunized groups. Immunization with
MOMP and CTA1-DD via the TC route only induced a
significant amount of IL-17 (P,0.001). With the exception of
the IN immunization with MOMP and CT/CpG (P,0.001), no
vaccine induced a significant amount of IL-10. IL-4 was not
detected in any vaccine group at levels above unimmunized
controls.
Antigen-specific proliferation and cytokine production
by lymphocytes isolated from the MdLN
Immunization with MOMP and CT/CpG via the SL (P,0.01)
or TC (P,0.001) routes, but not via the IN route, generated an
antigen-specific lymphoproliferative response in the MdLN,
significantly greater than unimmunized animals (Figure 5A). TC
immunization with MOMP and CTA1-DD also induced a
proliferative response in the MdLN, significantly higher than
control animals (P,0.05), but not when the vaccine was delivered
via the IN or SL routes.
Elevated levels of cytokine secretions were only detected in those
groups previously shown to have significantly increased prolifer-
ation in the MdLN in response to MOMP stimulation (Figure 5B).
This included the animals immunized with either vaccine by the
TC route with MOMP and both adjuvant and the group SL
immunized with MOMP and CT/CpG, groups that were also
protected against pathology (Figure 3B). Lymphocytes isolated
from these groups predominantly secreted IL-17 following
stimulation. IFNc was only detected in groups immunized via
the TC route, although significance was limited to the animals
immunized with MOMP and CT/CpG. TNFa, IL-4 and IL-10
were not found to be significantly elevated in any group.
Antigen-specific serum antibodies
The presence of Chlamydia-specific antibodies can also offer
protection against the establishment of infection and pathology
[29]. Serum IgG levels varied based on both adjuvant and
immunization route, but serum IgA production was unique to the
IN route and independent of adjuvant (Figure 6). The MOMP and
CT/CpG vaccine elicited significantly greater levels of MOMP-
Figure 2. Chlamydial burden in lung tissue at day 10 p.i determined by ompA PCR. Genomic DNA (gDNA) was extracted from lung tissues
collected at day 10 p.i. Chlamydial DNA was quantified from lung gDNA by ompA-specific qRT-PCR using a standard curve. The copies of C.
muridarum DNA per mg of host gDNA for each vaccine were grouped with their respective route of immunization. Results are presented as the mean
6 SD. Significant differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P,0.05 for all tests. P.0.05
(not shown), 0.01–0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g002
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specific IgG in serum than MOMP and CTA1-DD by any routes
(P,0.05–0.001). Consistent with results seen previously [18], the
addition of the CTA1-DD adjuvant to a MOMP-based vaccine
did not boost antigen-specific antibody titers when compared to
the antigen alone controls. Overall, the IN route appeared
superior to SL and TC routes for inducing a systemic antibody
response. Interestingly, there was no significant difference in IgG
titers between immunization with MOMP and CT/CpG via the
IN or TC route.
The combination of MOMP and adjuvants CT and CpG
induced the desired balanced Th1/Th2 response via all routes, as
shown by the IgG2a:IgG1 ratios of 1:1 (Figure 6). Similarly,
immunization with MOMP and CTA1-DD also elicited a
balanced Th1/Th2 response via the IN and SL route (1:1), but
a more Th2-dominant response by the TC (1:5) route. Immuni-
zation with the antigen alone, in the absence of a polarizing
adjuvant, by the IN (1:2) or TC routes (1:50) elicited, Th2-
dominant responses, whereas the SL route elicited a more
balanced response (1:1).
Immunization with MOMP together with CTA1-DD or CT/
CpG increased (between 10–50%) the Chlamydia-neutralizing
capabilities of the serum when compared to the antigen only
controls (Figure 6). There was however no significant differences in
the neutralizing capacities of the serum, between animals
immunized with either vaccine via any route. Despite the
similarities in MOMP-specific antibody titers between the
CTA1-DD-based vaccine and the antigen alone control, there
was a significant increase in the neutralizing capabilities of the
Figure 3. Fibrotic scarring and lung consolidation following IN infection with C. muridarum. Lung tissues collected at day 10 p.i were
paraffin embedded, sectioned and stained using Masson’s trichrome. (A) The pathology score scale used to compare the development of disease
following infection. Representative histological images for each pathology scores are depicted. ‘‘0’’ signifies healthy, undamaged lung tissue. Scores
of ‘‘1’’ through to ‘‘3’’ depict worsening degrees of collagen deposition (blue) and the beginnings of obstruction and consolidation of the lungs
(white arrows). Pathology can also be seen on a macroscopic level, when comparing healthy (left) and fibrotic (right) lobes of the lungs. (B) Average
pathology scores, determined by three separate individuals blinded to groups and experimental design. Results are presented as the mean 6 SD.
Significant differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P , 0.05 for all tests. P .0.05 (not
shown), 0.01–0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g003
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serum in animals immunized with the MOMP and CTA1-DD
(P,0.01–0.001). Moreover, there was a significant improvement
in the neutralizing potential of serum from animals immunized
with MOMP and CT/CpG via the SL compared to TC route
(P,0.01), despite the latter group inducing significantly higher
MOMP-specific IgG titers (P,0.01). The IN route was again the
most effective when compared to SL and TC routes, for the
production of neutralizing antibodies.
Antigen-specific mucosal antibodies
In the respiratory tract secretions there were no significant
differences in antibody titers (IgG or IgA) between animals
Figure 4. Proliferation and cytokine production by lymphocytes isolated from the spleen and stimulated with MOMP. Splenocytes
were stimulated with MOMP or media for 72 hr. (A) Lymphocyte proliferation was determined by addition of thymidine for an additional 14 hr. Data
are expressed as stimulation index (cpm of the MOMP stimulated cells divided by the cpm of media stimulated cells). (B) The amount of TNFa, IFNc,
IL-4, IL-10 and IL-17 (pg/mL) secreted by splenocytes following stimulation was quantified using BioplexH and ELISA. Results are presented as the
mean 6 SD. Significant differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P,0.05 for all tests.
P.0.05 (not shown), 0.01–0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g004
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immunized with MOMP and either CT/CpG or CTA1-DD, with
the exception of animals immunized via the TC route (Figure 7).
No IgA was detected following TC immunization; however, the
MOMP and CT/CpG vaccine did elicit a BAL IgG response by
the same route. IgA and IgG production was detected in the
mucosal secretions of animals immunized via the IN and SL route.
The neutralizing capacity of BAL was enhanced by both adjuvants
compared to immunization with MOMP alone, however this was
only found to be significant in the BAL of animals immunized via
the SL route (P,0.05–0.01).
Discussion
In this study, we assessed the level of protective immunity
generated against a chlamydial respiratory tract infection following
needle-free immunization with MOMP combined with two
Figure 5. Proliferation and cytokine production by lymphocytes isolated from the MdLN and stimulated with MOMP. Lymphocytes
isolated from the MdLN draining the lungs were stimulated with MOMP or media for 72 hr. (A) Lymphocyte proliferation was determined by
incubating the stimulated cells with thymidine for an additional 14 hr and expressed as stimulation index. (B) The amount of TNFa, IFNc, IL-4, IL-10
and IL-17 (pg/mL) secreted by the lymphocytes were quantified using BioplexH and ELISA. Results are presented as the mean 6 SD. Significant
differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P,0.05 for all tests. P.0.05 (not shown), 0.01–
0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g005
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different adjuvants. Immunization of animals with MOMP and
CT/CpG via the TC and SL routes significantly reduced
infection-associated weight loss and the amount of recoverable
chlamydial DNA from the lungs at day 10 p.i. This protection was
similar to the immunity acquired from a natural infection, but also
included near complete protection from pathology (fibrosis and
lung consolidation). Interestingly, MOMP and CT/CpG prevent-
ed both progressive weight loss and chlamydial burden regardless
of administration route. Conversely, MOMP together with CTA1-
DD was only protective against the infection following IN
administration. Induction of a strong serum IgG and splenic
cell-mediated response, dominated by pro-inflammatory cytokines
IFNc, TNFa, IL-17, was associated with the protection against
infection. A local pro-inflammatory cell-mediated response in the
lymph nodes draining the lungs however, determined whether
fibrotic scarring was prevented. Interestingly, the protection
against infection elicited by both IN delivered vaccines (reduced
weight loss and bacterial load) did not however, provide protection
from pulmonary fibrosis. Moreover, TC immunization with
MOMP and CTA1-DD prevented pathology despite having no
significant influence on chlamydial burden and a minimal effect on
weight loss. Therefore, this study not only identified vaccinations
that protect against both infection and pathology, but also
infection or pathology individually. This illustrates the challenges
involved when developing a vaccine against Chlamydia: should the
primary aim be to prevent infection (sterilizing immunity) or
prevent disease-associated pathology, as reducing the chlamydial
burden in the lungs does not necessarily protect against pathology
and vice versa, at least in this mouse model.
The route of immunization influenced the effectiveness of each
adjuvant; particularly CTA1-DD. IN immunization with either
vaccine elicited similar MOMP-specific immune responses.
However, immunization with MOMP and CT/CpG consistently
elicited stronger antigen-specific cell-mediated and humoral
responses than the CTA1-DD-containing vaccine, when both
vaccines were administered by the SL or TC routes. This
difference is likely linked closely with each adjuvant’s mechanism
of action, as well as the antigen-presenting cells (APCs) targeted
and their density/distribution at the site of immunization. CpG
activate toll-like receptor (TLR) 9 that is expressed by keratino-
cytes, Langerhan’s cells, plasmacytoid dendritic cells (DCs),
myeloid DCs, macrophages/monocytes, mast cells and B cells in
mice, which elicit a Th1-polarized response upon activation
through TLR9 [30]. CT binds all nucleated mammalian cells via
Figure 6. Antigen-specific systemic antibodies in serum. (A) MOMP-specific serum IgG, IgA IgG1 and IgG2a following vaccination was
quantified by direct ELISA. Endpoint tires were calculated for all samples using background absorbance of PBST plus two SD. The ratio of IgG2a:IgG1,
used to determine Th1:Th2 polarization, is indicated above the titer bars in each group. (B) Percentage of infection neutralized in vitro was
determined by incubation of Chlamydia with a 1/10 dilution of whole serum. Results are presented as the mean 6 SD. Significant differences were
determined using a one-way ANOVA with Tukey’s post-test. Significance was set at P,0.05 for all tests. P.0.05 (not shown), 0.01–0.05 (*), 0.001–0.01
(**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g006
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the GM1-ganglioside receptor to enhance Th2 as well as Th1
responses [31]. Together, both CpG and CT elicit a balance
between Th1 cell-mediated and Th2-driven humoral immunity,
crucial for a chlamydial vaccine. The success of CT/CpG by IN,
SL or TC routes of administration could be attributed to the
adjuvants’ capacity to target and stimulate a number of innate cell
populations localized at the site of immunization, thus enhancing
antigen uptake/presentation and the development of adaptive
immunity.
CTA1-DD is a non-toxic derivative of CT that retains the
immunomodulatory properties of the holotoxin i.e. Th1/Th2
polarizing response, but differs greatly in target cell binding.
CTA1-DD is thought to predominantly, but not exclusively, target
B cells as APCs [11]. Recently, CTA1-DD has been shown to bind
follicular DCs in B cell follicles in a CR2-dependent manner, to
enhance germinal centre reactions and T cell-dependent responses
by activation of the complement pathway [32]. The immunoge-
nicity of CTA1-DD, similar to CT, is highly dependent on binding
and internalization of the enzymatically active ADP-ribosyltran-
ferase subunit for optimal adjuvanticity [33]. This could explain
why CTA1-DD was immunogenic via the IN route, which targets
the B cell and follicular DC rich nasopharynx-associated lymphoid
tissue, but was less effective when administered via the TC and SL,
routes targeting tissues where these target cells are not normally
found in great numbers in a resting state [34,35].
In this study, the vaccinations that induced a significant amount
of protection from a respiratory tract infection, determined by
weight loss and chlamydial burden, generated the highest titers of
MOMP-specific serum antibodies. Serum antibodies have been
shown to neutralize Chlamydia in vitro and in vivo [36]. Additionally,
B cell-deficient mice challenged IN with C. muridarum have also
been shown to be more susceptible to re-infection, have higher
mortality rates and develop more severe cachexia compared to
WT mice [28,29]. This suggests that antibodies play an important
role in preventing and controlling infection in the chlamydial
respiratory tract model.
We also found that MOMP-specific IgG, and not IgA, was a
better associate of protection against a respiratory infection in vivo.
IgA has previously been shown to have no effect on the resolution
of a primary respiratory tract infection or the incidence of
mortality following passive immunization [37]. The IgA generated
in the serum following vaccination in our study, significantly
improved its neutralization of Chlamydia in vitro. However, this IgA
may not have possessed the necessary secretory component
required by the polyclonal immunoglobulin receptor (pIgR) to
transcytose IgA into the lumen to neutralize the infection in vivo, by
preventing microbial attachment. In addition, the expression of
pIgR has been shown to be absent in the murine lungs [38],
suggesting that even secretory IgA may be unable to enter the
respiratory tract effectively. The lack of protection offered by IgA
Figure 7. Antigen-specific mucosal antibodies in BAL. (A) The induction of MOMP-specific IgG and IgA in the BAL following vaccination was
quantified by direct ELISA. (B) Percentage of infection neutralized in vitro was determined by incubation of Chlamydia with a 1/10 dilution of BAL.
Results are presented as the mean6 SD. Significant differences were determined using a one-way ANOVA with Tukey’s post-test. Significance was set
at P,0.05 for all tests. P.0.05 (not shown), 0.01–0.05 (*), 0.001–0.01 (**) and ,0.001 (***).
doi:10.1371/journal.pone.0061962.g007
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in this study can be supported by the detection of low levels of IgA
in the BAL, which did not enhance neutralization in vitro or
associate with protection against infection in vivo. Therefore, IgA
was ineffective at mediating protection against infection in vivo,
possibly due to the induction of insufficient levels of IgA in the
mucosal secretions needed to inhibit chlamydial attachment.
Alternatively, IgG is able to passively transfuse from the serum into
the highly vascularized lung mucosal tissues. The inability of IgG
alone to neutralize Chlamydia infectivity in vitro as effectively as IgA
however, suggests that the protection mediated by IgG in vivo may
occur through Fc-dependent mechanisms as opposed to direct
neutralization [39].
Despite the positive influence that high serum antigen-specific
IgG titers had on protection against infection, the quantity, quality
or class of antibodies in the serum or mucosal secretions could be
associated with protection from pathology. IgA-deficient mice
display exaggerated lung histopathology following an IN infection,
even in the presence of a compensatory over-production of other
serum antibodies [37]. This suggests that IgG is ineffective at
preventing pathology, while IgA plays a role in regulating
pulmonary inflammation and mucosal homeostasis following a
primary chlamydial respiratory infection. The low levels of
MOMP-specific IgA detected in the BAL following vaccination,
which failed to neutralize the infection in vitro or provide protection
against infection in vivo, may have also been unable to regulate
inflammation and hence prevent pathology. Moreover, suboptimal
concentrations of IgG have even been associated with enhance-
ment of pathology [40]. MOMP-specific antibodies induced
following vaccination were therefore unable to prevent the
development of pathology following a respiratory tract challenge,
despite their positive influence on infection.
Surprisingly, IN immunization with MOMP alone generated
strong antigen-specific humoral and cell-mediated (preferentially
IL-17) responses that provided partial protection against the
infection. Genetically linking the MOMP with MBP improves the
solubility and correct conformational folding of the recombinant
protein [41,42], vital for production of neutralizing antibodies
[43]. However, MBP can also acts as an adjuvant [44–48].
Proteins fused with MBP elicit significantly more serum antibodies
than untagged proteins [45–47], as MBP is a TLR4 agonist that
stimulates cytokine production and expression of co-stimulatory
molecules on DCs [44]. This provides an explanation for why IN
immunization with recombinant MOMP, in the absence of an
adjuvant, elicits a strong antigen-specific response as opposed to
mucosal tolerance [49,50]. Furthermore, Zygmunt et al., (2009)
described a predisposition for immunization via the IN route to
promote Th17 immune responses due to an adjuvant-independent
over production of IL-6 by DC localized in the nasopharynx-
associated lymphoid tissue [51], which would also explain the
preferential induction of IL-17 when antigen is delivered
intranasally.
The vaccinations that elicited a significant level of protection
against weight loss and infectious burden following an respiratory
infection, induced secretion of the pro-inflammatory cytokine
TNFa, IL-17 and IFNc by splenocytes following in vitro re-
stimulation with MOMP. These same immunizations also elicited
low-level secretion of the anti-inflammatory cytokines IL-4 and IL-
10 by splenocytes. As the induction of pro-inflammatory cytokines
(IFNc, TNFa and IL-17) by T cells is known to enhance the
resolution of infection [28,52-55] and anti-inflammatory cytokines
(IL-4 and IL-10) inhibit the clearance of a chlamydial respiratory
tract infection [28,52], these vaccinations primed the ideal
response necessary to eradicate an active infection.
Pro-inflammatory cytokines, IFNc, TNFa and IL-17 have been
shown to act individually and synergistically to improve inhibition
of chlamydial growth. IFNc-mediated inhibition of Chlamydia
growth in vitro is enhanced 2-fold in the presence of TNFa [56,57].
The synergism between IFNc and TNFa is likely to be heightened
further in vivo, as TNFa-mediated inhibition of chlamydial growth
is indirect and requires the recruitment of additional cell
populations [58]. TNFa and IFNc can also synergize with IL-17
to up-regulate intercellular adhesion molecule 1 [59,60], which is
associated with immune cell recruitment, activation of the Th1
response and the normal resolution of a chlamydial genital tract
infection [61,62]. In addition, the induction of CD4+ T cells
secreting a combination of cytokines (IFNc+TNFa+ and IL-
17+IFNc+ double positives, specifically) following vaccination has
been shown by others as an excellent correlate of protection
against a chlamydial genital tract infection [63,64]. Therefore, the
production of IFNc, TNFa and IL-17 following immunization
coincided with strong protection against infection, potentially due
to a synergistic interaction between multiple pro-inflammatory
cytokines. To the best of our knowledge, this is the first evidence of
this combination cytokine response, first mentioned by Igiesteme et
al., (1993) and Yu et al., (2010), conferring protection against
Chlamydia in the respiratory tract infection model. Although we
cannot definitively say whether CD4+ T cells were co-producing
these cytokines upon re-stimulation with MOMP, the quality of T
cells and the development of a multi-functional phenotype can be
influenced by the adjuvant [64], duration of antigen exposure
[65], the type of APCs targeted [66] and the innate cytokine milieu
at the site of immunization [67]
Unexpectedly, we were unable to detect an IFNc response in
the spleen or MdLN following SL immunization with MOMP plus
CT/CpG, even though this group of animals was significantly
protected against infection. It is possible that IFNc-secreting
MOMP-specific cells were present locally, instead adopting a more
effector phenotype and migrating to other non-lymphoid tissues
[68]. Alternatively, the lymphocytes may have produced IFNc
following antigenic stimulation at a point in time not chosen for
cytokine analysis [69].
Our data indicated that protection against infection was
associated with a strong pro-inflammatory cell-mediated response
in the spleen. TNFa and IFNc are known to be potent inhibitors
of fibrosis [70], although the production of these cytokines by
splenocytes in this study could not be linked with protection
against pathology. However, when a significant level of local
antigen-specific proliferation and cytokine production was detect-
ed in the MdLN draining the respiratory tract, protection against
infection increased significantly and extended to include the
prevention of pathology. The enhancement of protection against
infection and pathology seen in these groups may reflect the ability
of an antigen-specific cell-mediated response residing in the lymph
nodes draining the site of infection to respond more rapidly than a
splenic response [71,72]. Support for this hypothesis is provided by
our findings that groups mounting a local response in the lymph
nodes draining the site of infection following vaccination (TC or
SL immunization with MOMP and CT/CpG), were more
resistant to weight loss earlier during the course of infection,
when compared to animals IN immunized with MOMP and CT/
CpG, that only mounted a systemic response. Therefore,
protection against pathology following a respiratory challenge
with Chlamydia may rely on a vaccine priming and positioning a
cell-mediated response in the regional lymph nodes, that can
respond early during an infection and potentially limit the
involvement of the innate response in eradicating the infection.
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Interestingly, there appeared to be a significant disconnection
between infection and pathology in some vaccine groups, where a
reduction in chlamydial burden did not necessarily coincide with
protection against inflammatory disease and vice versa. Both IN
delivered vaccines elicited protection from infection, yet seemed to
exacerbate pathology compared to that of a normal course of
infection. IN immunization elicited the strongest pro-inflammato-
ry cytokine response that may have caused an imbalance between
the control of infection and prevention of disease, resulting in
excessive immunopathology [73]. Alternatively, it is conceivable
that trace amounts of the vaccine may have drained into the lungs
[74] and caused local inflammation and fibrosis, interpreted as
infection-induced pathology.
This does not appear to be the case for the TC delivered CTA1-
DD-adjuvanted vaccine group, which was solidly protected from
pathology despite having no significant reduction in the infectious
burden. Although the underlying mechanisms in this case are
unknown, it has been suggested that inducible tolerogenic
pathways protective against disease could exist for many types of
infection, including Chlamydia [75]. Identifying and understanding
these pathways may form the basis for new treatment strategies
that could include vaccines.
In conclusion, the CTA1-DD adjuvant has been shown to elicit
strong protection against a number of respiratory tract pathogens
[13,15], which now includes Chlamydia. CTA1-DD also represents
the next generation of non-toxic mucosal adjuvants found to be
safe in primates [12] and its adjuvanticity and safety in humans is
currently under investigation. The CT/CpG adjuvant combina-
tion could potentially be used for TC immunization in humans.
The TC route would minimize the toxicity associated with IN and
SL delivery of CT in humans. Alternatively, replacing CT with
CTA1-DD may allow the safe use of a CTA1-DD/CpG
combination, delivered by either the SL or IN routes, in humans.
Studies are currently in progress to evaluate the effectiveness of
this adjuvant combination in our animal model. The induction of
high serum MOMP-specific IgG, but not IgA, was associated with
protection against infection and this was largely mirrored in the
mucosal secretions. Systemic pro-inflammatory cell-mediated
responses were also associated with the enhanced resolution of
infection, possibly due to the synergistic effect of IFNc, TNFa and
IL-17. Detection of antigen-specific cell-mediated responses in the
lymph nodes draining the lungs were associated with protection
against pathology, which may reflect the time required to initiate
and recruit an immune response to the site of the infection.
Interestingly, protection against pathology developed in cases
when the chlamydial DNA recovered from the lung tissue was
unaltered. This suggested that there may be other immunopath-
ological mechanisms modulating the development of disease
following infection, which are independent of infection control
and could be potential targets for future vaccines.
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